rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VTGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      VistaGen Therapeutics earnings beat by $0.14, revenue fell short of estimates
      Nov 16Investing.comVTGN
      Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

      Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibilitySOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported fina

      Nov 13Yahoo FinanceVTGN
      Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
      Nov 9Yahoo FinanceVTGN
      Vistagen partners with GATC Health on AI drug development
      Oct 20Investing.comVTGN
      VistaGen Therapeutics Updates Executive Severance and Control Plan

      Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailVTGN
      VistaGen Updates Strategy for Pherine-Based CNS Therapies

      Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailVTGN
      Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
      Sep 24Yahoo FinanceVTGN
      Vistagen presents exploratory data on social anxiety treatment
      Sep 24Investing.comVTGN
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)

      Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCDXSVTGN
      Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
      Sep 24Yahoo FinanceVTGN
      12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

      Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

      Sep 23BenzingaADGMARTLJAGXVTGN
      Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Vistagen Therapeutics (NASDAQ:VTGN)

      Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.

      Sep 23BenzingaVTGN
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Vistagen Ther

      Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by

      Sep 23BenzingaVTGN
      Top Premarket Gainers

      Vistagen Therapeutics (VTGN) shares were up 68% in Wednesday premarket activity after the company an

      Sep 23Yahoo FinanceVTGN
      Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
      Sep 22Yahoo FinanceVTGN
      Vistagen Therapeutics shareholders elect board members and approve key proposals
      Sep 11Investing.comVTGN
      Vistagen to Present at Psych Congress 2026

      Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorderSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Ph

      Sep 10Yahoo FinanceVTGN

      This is the newest page. Registered accounts read further back.